ArticleESMO open2016

Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP).

Ana Fröbe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.